Rudy Li
Stock Analyst at Wolfe Research
(4.89)
# 265
Out of 4,356 analysts
80
Total ratings
60.3%
Success rate
74.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $33 | $21.66 | +52.35% | 2 | May 6, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $160 | $158.30 | +1.07% | 2 | Apr 6, 2026 | |
| PRAX Praxis Precision Medicines | Maintained: Buy | $500 | $349.97 | +42.87% | 7 | Apr 6, 2026 | |
| CNTA Centessa Pharmaceuticals | Downgraded: Hold | n/a | $39.76 | - | 6 | Mar 31, 2026 | |
| ALKS Alkermes | Initiated Coverage: Buy | $45 | $42.19 | +6.66% | 2 | Feb 23, 2026 | |
| QURE uniQure | Initiated Coverage: Hold | n/a | $28.53 | - | 1 | Feb 23, 2026 | |
| XENE Xenon Pharmaceuticals | Initiated Coverage: Buy | $55 → $60 | $54.73 | +9.63% | 5 | Feb 23, 2026 | |
| AXSM Axsome Therapeutics | Initiated Coverage: Buy | $230 | $234.48 | -1.91% | 1 | Feb 23, 2026 | |
| DFTX Definium Therapeutics | Initiated Coverage: Buy | $20 → $25 | $24.19 | +3.35% | 11 | Feb 23, 2026 | |
| LON: 0NZT UCB SA | Initiated Coverage: Buy | €340.00 | $244.16 | +39.25% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $21.04 | - | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 → $40 | $30.91 | +29.41% | 19 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $10.18 | +76.82% | 15 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $14.96 | +100.53% | 2 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $20.07 | -25.26% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $40 | $0.409208 | +9,674.98% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $110.40 | $123.46 | n/a | 2 | May 21, 2025 |
ACADIA Pharmaceuticals
May 6, 2026
Reiterated: Buy
Price Target: $33
Current: $21.66
Upside: +52.35%
Neurocrine Biosciences
Apr 6, 2026
Reiterated: Buy
Price Target: $160
Current: $158.30
Upside: +1.07%
Praxis Precision Medicines
Apr 6, 2026
Maintained: Buy
Price Target: $500
Current: $349.97
Upside: +42.87%
Centessa Pharmaceuticals
Mar 31, 2026
Downgraded: Hold
Price Target: n/a
Current: $39.76
Upside: -
Alkermes
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $42.19
Upside: +6.66%
uniQure
Feb 23, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $28.53
Upside: -
Xenon Pharmaceuticals
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $55 → $60
Current: $54.73
Upside: +9.63%
Axsome Therapeutics
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $230
Current: $234.48
Upside: -1.91%
Definium Therapeutics
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $20 → $25
Current: $24.19
Upside: +3.35%
UCB SA
Feb 23, 2026
Initiated Coverage: Buy
Price Target: €340.00
Current: $244.16
Upside: +39.25%
Feb 23, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $21.04
Upside: -
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $24 → $40
Current: $30.91
Upside: +29.41%
Dec 31, 2025
Initiated Coverage: Buy
Price Target: $18
Current: $10.18
Upside: +76.82%
Dec 31, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $14.96
Upside: +100.53%
Oct 20, 2025
Maintained: Buy
Price Target: $15
Current: $20.07
Upside: -25.26%
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $40
Current: $0.409208
Upside: +9,674.98%
May 21, 2025
Reiterated: Buy
Price Target: $110.40
Current: $123.46
Upside: n/a